Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.
Zegels, Brigitte; Crozes, P.; Uebelhart, D.et al.
2013 • In Osteoarthritis and Cartilage, 21 (1), p. 22-27
[en] OBJECTIVE: Evaluation of the efficacy and safety of a single oral dose of a 1200 mg sachet of chondroitin 4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400) (equivalence study) and vs placebo (superiority study) during 3 months, in patients with knee osteoarthritis (OA). DESIGN: Comparative, double-blind, randomized, multicenter study, including 353 patients of both genders over 45 years with knee OA. Minimum inclusion criteria were a Lequesne index (LI) >/= 7 and pain >/= 40 mm on a visual analogue scale (VAS). LI and VAS were assessed at baseline and after 1-3 months. Equivalence between CS was tested using the per-protocol procedure and superiority of CS vs placebo was tested using an intent-to-treat procedure. RESULTS: After 3 months of follow-up, no significant difference was demonstrated between the oral daily single dose of CS 1200 formulation and the three daily capsules of CS 400. Patients treated with CS 1200 or CS 3*400 were significantly improved compared to placebo after 3 months of follow-up in terms of LI (<0.001) and VAS (P < 0.01). No significant difference in terms of security and tolerability was observed between the three groups. CONCLUSION: This study suggests that a daily administration of an oral sachet of 1200 mg of chondroitin 4&6 sulfate allows a significant clinical improvement compared to a placebo, and a similar improvement when compared to a regimen of three daily capsules of 400 mg of the same active ingredient.
Disciplines :
General & internal medicine
Author, co-author :
Zegels, Brigitte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Crozes, P.
Uebelhart, D.
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.
Publication date :
2013
Journal title :
Osteoarthritis and Cartilage
ISSN :
1063-4584
eISSN :
1522-9653
Publisher :
W.B. Saunders, London, United Kingdom
Volume :
21
Issue :
1
Pages :
22-27
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Arden N., Nevitt M.C. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20:3-25.
Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through. Osteoarthritis Cartilage January 2009, 18:476-499.
Bruyere O., Burlet N., Delmas P.D., Rizzoli R., Cooper C., Reginster J.Y. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008, 9:165.
Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 2008, 67:735-740.
Reginster J.Y., Heraud F., Zegels B., Bruyere O. Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Rev Med Chem 2007, 7:1051-1061.
Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
Michel B.A., Stucki G., Frey D., De Vathaire F., Vignon E., Bruehlmann P., et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005, 52:779-786.
Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl 3):S19-S21.
Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010, 18(Suppl 1):S28-S31.
Hochberg M.C., Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate *. Curr Med Res Opin 2008, 24:3029-3035.
Bruyere O., Reginster J.Y. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007, 24:573-580.
Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049.
Lequesne M. Indices of severity and disease activity for osteoarthritis. Semin Arthritis Rheum 1991, 20:48-54.
Lequesne M.G., Mery C., Samson M., Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987, 65:85-89.
Bourgeois P., Chales G., Dehais J., Delcambre B., Kuntz J.L., Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthritis Cartilage 1998, 6(Suppl A):25-30.
Uebelhart D., Malaise M., Marcolongo R., de Vathaire F., Piperno M., Mailleux E., et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004, 12:269-276.
Bucsi L., Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998, 6(Suppl A):31-36.
Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996, 23:1385-1391.
Blotman F., Loyau G. Clinical trial with chondroitin sulfate in gonarthrosis. Osteoarthritis Cartilage 1993, 1:68.
Richter A., Anton S.E., Koch P., Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther 2003, 25:2307-2335. discussion 06.
Eraker S.A., Kirscht J.P., Becker M.H. Understanding and improving patient compliance. Ann Intern Med 1984, 100:258-268.
Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
Andrejak M., Genes N., Vaur L., Poncelet P., Clerson P., Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 2000, 13:184-190.
Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., Przybeck T.R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990, 150:1881-1884.
Bruyere O., Scholtissen S., Neuprez A., Hiligsmann M., Toukouki A., Reginster J.Y. Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. J Med Econ 2009, 12:356-360.
Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522.